- Home
- ANAB vs MLKN Comparison
ANAB vs MLKN Comparison
Compare ANAB & MLKN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANAB | MLKN |
|---|---|---|
| Founded | 2005 | 1905 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Office Equipment/Supplies/Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2015 | 1994 |
Fundamental Metrics
Financial Performance| Metric | ANAB | MLKN |
|---|---|---|
| Price | $53.61 | $22.56 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $71.67 | N/A |
| AVG Volume (30 Days) | ★ 818.3K | 766.9K |
| Earning Date | 05-08-2026 | 03-25-2026 |
| Dividend Yield | N/A | ★ 4.71% |
| EPS Growth | 91.02 | ★ 344.44 |
| EPS | N/A | ★ 1.32 |
| Revenue | $234,603,000.00 | ★ $3,841,700,000.00 |
| Revenue This Year | N/A | $5.94 |
| Revenue Next Year | $52.14 | $3.78 |
| P/E Ratio | ★ N/A | $16.73 |
| Revenue Growth | ★ 157.01 | 4.68 |
| 52 Week Low | $17.11 | $13.77 |
| 52 Week High | $73.30 | $23.18 |
Technical Indicators
Market Signals| Indicator | ANAB | MLKN |
|---|---|---|
| Relative Strength Index (RSI) | 44.82 | 68.46 |
| Support Level | $52.32 | $18.05 |
| Resistance Level | $57.70 | $23.18 |
| Average True Range (ATR) | 4.55 | 0.87 |
| MACD | -0.98 | -0.03 |
| Stochastic Oscillator | 24.72 | 84.93 |
Price Performance
Historical ComparisonAbout ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About MLKN MillerKnoll Inc.
MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract, International Contract, and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.